齐拉西酮与舒必利治疗精神分裂症疗效与安全性比较

目的比较齐拉西酮与舒必利治疗精神分裂症的疗效与安全性。方法120例精神分裂症患者随机分为2组,分别服用齐拉西酮（130.35±30.75）mg/d;60例]或舒必利（1.1±0.5）g/d;60例],疗程为8周。采用阳性和阴性症状量表（PANSS）、不良反应量表（TESS）与治疗前和治疗后第1、2、4、6、8周末分别评定疗效和不良反应。结果①齐拉西酮组的有效率为86.7%,舒必利组为83.3%,2组比较差异无统计学意义（P〉0.05）;②2组治疗8周后,PANSS总分、阳性症状分、阴性症状分及一般精神病理分与治疗前比较均有显著性差异（P〈0.05）,而治疗8周时2组减分率差异无统计学意义;③治疗8周后2组肝功能、心电图异常率比较,均差异无统计学意义（P〉0.05）。齐拉西酮组主要不良反应为嗜睡、恶心、便秘、厌食。舒必利组不良反应主要为心动过速、口干、便秘、体质量增加、锥体外系反应。结论齐拉西酮与舒必利在治疗精神分裂症时疗效相当,不良反应发生率基本一致,但临床表现各异。

Ziprasidone vs Sulpiride in the Treatment of Schizophrenia Compared the Efficacy and Safety

Objective To compare ziprasidone with sulpiride in the treatment of schizophrenia and security.Methods One hundred and twenty patients with schizophrenia were randomly divided into two groups：ziprasidone group n=60,ziprasidone（130.35±30.75）mg/d];and Sulpiride group （n= 60,sulpiride（1.1±0.5）g/d],and both groups were treated for 8 weeks.The positive and negative symptom scale（PANSS） and treatment emergent symptom scale（TESS） were used to determine the results before treatment and on the weekend of 1,2,4,6,and 8 weeks after treatment to assessed the efficacy and side effects,respectively.Results ①ziprasidone group response rate was 86.7%and sulpiride group was 83.3%.There was no statistically significant difference（P〉0.05）.②After 8 weeks treatment,PANSS groups total score,positive symptoms,negative symptoms and general psychiatric sub-points compared with those before treatment were significantly different（P〈0.05）,while treatment of 8 weeks reduced rate of the two groups was no significant difference.③After 8 weeks,both anti-dysfunction and ECG abnormalities were not significant different（P〉0.05）.Major The adverse reactions in Ziprasidone group were drowsiness,nausea,constipation,loss of appetite.Those in Sulpiride group were mainly tachycardia,dry mouth,constipation,weight gain,extrapyramidal reactions.Conclusion Ziprasidone and sulpiride in the treatment of schizophrenia when the effects equivalent to the incidence of adverse reactions are basically the same,but different clinical manifestations.